<DOC>
	<DOC>NCT02751060</DOC>
	<brief_summary>The purpose of this study is to determine whether the expression level of miR-320a are effective as biomarker in evaluating the diagnosis, prognosis and treatment effects of coronary heart disease.</brief_summary>
	<brief_title>Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1. 18 years of age or older; 2. the most recent symptoms of coronary heart disease within 7 days; 3. meet one of the following conditions: A. clinical history of typical ischemic chest pain (more than 5 minutes of persistent chest pain); B. serum cardiac biomarkers positive (TnT/I or creatine kinase peak greater than 99% of URL); C. Electrocardiogram changes of myocardial ischemia. 1. pregnant women or plan to; 2. participate in any drug clinical trials within 3 months; 3. patients with lifethreatening complications, or the researchers determined that the survival time of patients with no more than 1 years; 4. serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients); 5. previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix); 6. patients refused to comply with the requirements of this study to complete the research work; 7. according to the researchers, patients can not complete the study or not to comply with the requirements of this study (because of the reasons for the management or other reasons).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>